Dr. Lowentritt on a Real-World Analysis of Apalutamide and Enzalutamide in mCSPC

Benjamin H. Lowentritt, MD, FACS, director, Minimally Invasive Surgery and Robotics, director, Prostate Cancer Care Program, Chesapeake Urology, president, AUA, MidAtlantic Region, discusses the real-world analysis of apalutamide (Erleada) and enzalutamide (Xtandi) in metastatic castration-sensitive prostate cancer (mCSPC).

Conducting a real-world analysis was difficult in the past; however, researchers are finding data can be extracted from appropriate patients if they are accessible, Lowentritt says. This study provided an opportunity to examine data from a system that works in several community urology groups, Lowentritt adds.

To complete the analysis, patient data were retrieved and examined. Though this method will never duplicate what comes out of a prospective randomized trial, it provides an insight into real-world and what impacts these the treatments are having, Lowentritt continues. Work on medication adherence and some other issues led to this real-world analysis, Lowentritt concludes.